Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kawashima, I.
Right arrow Articles by Tai, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawashima, I.
Right arrow Articles by Tai, T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

J. Biochem, 1990, Vol. 108, No. 1 109-115
© 1990 Japanese Biochemical Society


research-article

Monoclonal Antibodies to Disialogangliosides: Characterization of Antibody-Mediated Cytotoxicity against Human Melanoma and Neuroblastoma Cells In Vitro1

Ikuo Kawashima*, Nobuhiko Tada**, Takao Fujimori*** and Tadashi Tai*

*Department of Tumor Immunology, The Tokyo Metropolitan Institute of Medical Science Bunkyo-ku, Tokyo 113
**Department of Pathology, Tokai University School of Medicine Isehara, Kanagawa 250-11
***Meiji Institute of Health Science Odawara, Kanagawa 250

We previously reported the binding specificities of two anti-ganglioside GD2 murine monoclonal antibodies (MAbs), A1-425 and A1-267, both of which are of IgG3 isotype. A1-425 reacts specifically with ganglioside GD2, whereas A1-267 binds preferentially to GD2 but also reacts with GD3 [Tai, T., Kawashima, I., Tada, N., & Dairiki, K. (1988) J. Biochem. 103, 682–687]. In this paper, they were used for comparative analyses of antibody-mediated cytotoxicity, i.e., antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against human melanoma and neuroblastoma cell lines. Melanoma cells were found to contain GD2 and/or GD3, whereas neuroblastoma cells expressed only GD2. Both antibodies induced high levels of ADCC and CDC to GD2/ GD3-positive cells with human peripheral large granular lymphocytes (LGL) as effector cells and in the presence of human serum, respectively. A good correlation was obtained between the contents of disialogangliosides and the binding level of the antibodies; both melanoma and neuroblastoma cells with larger amounts of GD2/GD3 showed a higher level of antibody binding than did the cells with a smaller amount of GD2/GD3. Surprisingly, ADCC did not correlate well with the binding level of the antibodies. Thus, A1-425 showed stronger lytic activity than A1-267 in spite of the binding level of A1-425 being similar to or lower than that of A1-267 on the cell surfaces. Antigen-antibody complexes composed of GD2 and A1-425 showed higher binding levels to LGL than complexes of GD2 and A1-267. In contrast, free MAb molecules gave minimum binding to LGL. An anti-human Fc-receptors (III) MAb specifically inhibited both the binding of the antigen-antibody complex to LGL and the ADCC by the MAbs with LGL. These findings demonstrate that MAbs having high binding levels to Fc-receptors (III), as well as having specificities towards multiple ganglioside antigens, possess the strongest cytotoxicity against human tumor cells in ADCC.

1This work was supported in part by a grant from the Science and Technology Agency of Japan and by a Grant-in-aid for Cancer Research and a Grant-in-aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
Y. Azuma, Y. Ishikawa, S. Kawai, T. Tsunenari, H. Tsunoda, T. Igawa, S.-i. Iida, M. Nanami, M. Suzuki, R. F. Irie, et al.
Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of Melanoma
Clin. Cancer Res., May 1, 2007; 13(9): 2745 - 2750.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.